Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Cipla Ltd. Share Price
Day's Range
Low
₹1,347.00
High
₹1,372.50
Price Summary
| Previous Close | ₹1,358.00 |
|---|---|
| Day's Range | ₹1,347.00 - ₹1,372.50 |
| Open | ₹1,357.70 |
| 52 Week Range | ₹1,165.70 - ₹1,593.30 |
| Volume | 11,41,230 |
| Market Cap | ₹0.11 |
| Previous Close | ₹1,357.00 |
|---|---|
| Day's Range | ₹1,347.25 - ₹1,372.10 |
| Open | ₹1,360.10 |
| 52 Week Range | ₹1,165.55 - ₹1,598.70 |
| Volume | 43,276 |
| Market Cap | ₹0.11 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 15,497.90 |
|---|---|
| Market Cap (₹ in Mn) | 0.11 |
| Dividend Yield(%) | 0.96 |
| Price/Earning (TTM) | 37.93 |
| TTM EPS (₹) | 35.86 |
| P/E Ratio | 25.47 |
| Book Value(₹) | 3.10 |
| PAT Margin (%) | 9.92 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 16.00 |
| Trade Value ( ₹ in Lacs) | 587.26 |
|---|---|
| Market Cap (₹ in Mn) | 0.11 |
| Dividend Yield(%) | 0.96 |
| Price/Earning (TTM) | 37.93 |
| TTM EPS (₹) | 35.86 |
| P/E Ratio | 25.47 |
| Book Value(₹) | 3.10 |
| PAT Margin (%) | 9.92 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 16.00 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 75894.4 | 275476.2 |
| Expenses | N/A | N/A |
| PBT | 18538.3 | 67989.6 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 13533.7 | 52692.0 |
About Cipla Ltd.
| Founded | 1935 |
|---|---|
| Managing Director | Achin Gupta |
| NSE Symbol | CIPLA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,21,803.09 | 1,762.95 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,53,833.09 | 9,655.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,73,461.06 | 4,564.10 | 3,532.60 - 3,532.60 |
| Lenskart Solutions Ltd. | 1,19,959.95 | 678.80 | 0.00 - 0.00 |
| Laurus Labs Ltd. | 1,18,055.52 | 2,245.00 | 917.95 - 917.95 |
| Apollo Hospitals Enterprise Ltd. | 1,17,040.71 | 8,198.00 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,16,907.45 | 1,186.00 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,11,463.21 | 1,338.50 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,09,870.40 | 1,357.00 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,02,583.88 | 2,461.20 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Cipla informs about change in directorate
Cipla informs about grant of stock option
Cipla informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (InvaGen) (wholly owned subsidiary of the Company) located in Hauppauge, Long Island, New York, USA from 19th October, 2026 to 22nd October 2026 (ET). The Inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. The inspection concluded with zero Form 483 observations.
The above information is a part of company’s filings submitted to BSE.
Cipla informs about update
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to its intimation dated 10th February, 2026 regarding the Pre-Approval Inspection (PAI) conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals, Inc. (‘InvaGen’), a wholly-owned subsidiary of the Company, located in Hauppauge, Long Island, New York, USA, Cipla has informed that InvaGen has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection.
The above information is a part of company’s filings submitted to BSE.
iStreet Network informs about updates
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Cipla Ltd. is ₹1,358.00 as of 2026-10-29.
The market capitalisation of Cipla Ltd. is ₹109,870.40 as of 2026-10-28.
The 1-year return of Cipla Ltd. is -210.10% as of 2026-10-29.
The P/E ratio of Cipla Ltd. is 25.47 as of 2026-10-29.
The 52-week high and low of Cipla Ltd. are ₹1,593.30 and ₹1,165.70, respectively, as of 2026-10-29.
People Also Ask
Cipla operates across India, North America, Africa, Europe, and emerging markets. Its business includes branded and generic formulations, APIs, and consumer healthcare. Revenue is geographically diversified, with India and North America as key contributors. Cipla maintains a broad product portfolio supported by manufacturing facilities across multiple regions.
Key evaluation factors include Cipla's leadership in therapeutic portfolios, new product launches, EBITDA and margin trends, R&D pipeline, regulatory approvals, manufacturing compliance, and innovations in biosimilars and complex therapies.
Cipla’s portfolio includes respiratory, cardiology, central nervous system, oncology, anti-retroviral, urology, and anti-infective medicines. Operations primarily focus on small-molecule formulations and generics. Advanced therapies such as CAR-T or mRNA remain at early research or exploratory stages, not commercial operations.
Performance drivers include pharmaceutical pricing regulations, new product launches, clinical trial success rates, regulatory approvals (e.g., USFDA), competitive pressures, healthcare spending, API cost changes, manufacturing utilization, and the demand for specialty therapies.
Cipla operates across prescription pharmaceuticals, generic medicines, consumer healthcare products, and API manufacturing. These segments support its presence in both regulated and emerging markets through branded, unbranded, and over-the-counter offerings.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
